Emily Mullin

Emily Mullin
Emily
Mullin

<p><strong>Emily Mullin</strong>,
<em>Associate Editor</em></p>
<p>Before joining the Fierce life sciences team as an associate editor, Emily Mullin was a reporter at the <em>Baltimore Business Journal</em>, where she covered the healthcare and biotechnology industries, and a staff writer for Dorland Health, a healthcare trade publishing company based in Rockville, MD. She has served as a contributing writer to <em>The Maryland Daily Record</em>, where she’s covered topics ranging from neuroscience to hospital consolidation. Her business and healthcare stories have also appeared in <em>Nephrology Times</em>, <em>Columbus Business First</em> and the <em>Cincinnati Business Courier</em>. She is based in Washington, DC, and is a graduate of the E.W. Scripps School of Journalism at Ohio University. You can contact her at <a href="mailto:[email protected]">[email protected]</a>&nbsp;and follow her on Twitter at&nbsp;<a href="https://twitter.com/EmilyMFierce">@EmilyMFierce</a&gt;.

Stories by Emily Mullin

BioNano Genomics hooks $68.4M for tech that spots 'inaccessible genome'

Gene mapping outfit BioNano Genomics is hoping to set itself apart in the personalized medicine market, where a number of gene sequencing competitors are lining up. To help it get its technology to patients, the San Diego-based company has raised $68.4 million in a series C financing round, according to a regulatory filing.

Claritas Genomics brings in $15M Series B for pediatric diagnostics

Boston Children&#39;s Hospital spinoff Claritas Genomics has roped in $15 million in capital in a Series B round to help launch a new slate of next-generation sequencing-based tests for the diagnosis of pediatric genetic disorders. The Cambridge, MA-based company also plans to use the cash influx to continue to build its network of clinical pediatric disease experts.

Protein analysis method could act as new cancer biomarker

Researchers at Florida&#39;s Moffitt Cancer Center are gaining deeper insight into the biological processes going on inside a tumor in an effort to battle cancer more effectively. They&#39;ve developed a new technique to analyze specific protein complexes in cancer specimens.